
This Q&A interview segment with Harrison Nguyen, MD, MBA, MPH, highlights key points made during his 2026 Fall Clinical Dermatology meeting sessions.
The FDA-approved Scanly, a home-based OCT device, revolutionizes nAMD care by empowering patients with self-monitoring and enhancing personalized treatment.
When a breakthrough therapy receives US Food and Drug Administration (FDA) approval, it represents years of research, clinical trials, and collaboration to bring an additional weapon to the physician’s arsenal. But as revolutionary as these treatments may be, their impact is often inseparable from the tools used to track their effects.






